Read by QxMD icon Read

Urologic Oncology

Htoo Zarni Oo, Roland Seiler, Peter C Black, Mads Daugaard
Over the past decade, genomic and transcriptomic analyses have uncovered promising tumor antigens including immunotherapeutic targets in bladder cancer (BCa). Conventional tumor antigens are proteins expressed on the plasma membrane of tumor cells such as EGFR, FGFR3, and ERBB2 in BCa, which can be targeted by antibodies or similar epitope-specific binding reagents. The cellular proteome consists of ∼100,000 proteins but the expression of these proteins is rarely unique to tumor cells. Many tumor-associated proteins are post-translationally modified with phosphorylation, glycosylation, ubiquitination, or SUMOylation moieties...
October 17, 2018: Urologic Oncology
Tyler Etheridge, Jane Straus, Mark A Ritter, David F Jarrard, Wei Huang
BACKGROUND: Alpha methylacyl A coenzyme racemase (AMACR) has shown to be an excellent immunohistological biomarker for prostate cancer (CaP). Given the connection between prostate and urethra, we hypothesized that semen ejaculate would be an ideal specimen for detection of CaP specific biomarkers, such as AMACR. This study explores the detection of semen AMACR protein in men with and without CaP. METHODS: Semen ejaculates from 28 biopsy proven CaP patients prior to radical prostatectomy and 15 age-comparable controls were analyzed...
October 15, 2018: Urologic Oncology
Roy Mano, Sofia Zilber, Renzo G Di Natale, Daniel Kedar, David A Lifshitz, Ofer Yossepowitch, Jack Baniel, David Margel
OBJECTIVES: High-grade nonmuscle-invasive urothelial tumors of the bladder that fail intravesical Bacillus Calmette-Guérin (BCG) immunotherapy are at the highest risk of progression. Initial evidence links heat shock protein expression levels and outcome of bladder cancer after BCG treatment. We aimed to determine the association between HSP60, 70, and 90 expression levels and long-term outcomes of T1 high-grade (T1HG) urothelial bladder tumors treated with BCG immunotherapy. MATERIALS AND METHODS: Data of 54 consecutive patients with primary T1HG bladder tumors who underwent transurethral resection between 2002 and 2008 and received at least an induction course of BCG were reviewed...
October 15, 2018: Urologic Oncology
Sebastian L Hofbauer, Michela de Martino, Ilaria Lucca, Andrea Haitel, Martin Susani, Shahrokh F Shariat, Tobias Klatte
INTRODUCTION: Bladder cancer (BC) is diagnosed by cystoscopy, which is invasive, costly and causes considerable patient discomfort. MicroRNAs (miR) are dysregulated in BC and may serve as non-invasive urine markers for primary diagnostics and monitoring. The purpose of this study was to identify a urinary miR signature that predicts the presence of BC. METHODS: For the detection of potential urinary miR markers, expression of 384 different miRs was analyzed in 16 urine samples from BC patients and controls using a Taqman™ Human MicroRNA Array (training set)...
October 12, 2018: Urologic Oncology
Franziska Büscheck, Christoph Fraune, Ronald Simon, Martina Kluth, Claudia Hube-Magg, Christina Möller-Koop, Navid Shadanpour, Clemens Bannenberg, Christian Eichelberg, Doris Höflmayer, Till Clauditz, Corinna Wittmer, Waldemar Wilczak, Guido Sauter, Margit Fisch, Michael Rink, Till Eichenauer
OBJECTIVE: Antibodies against carbonic anhydrase IX (CAIX) are often part of immunohistochemical panels used to assist renal cell cancer (RCC) subtyping. This study was undertaken to determine, whether assessing CAIX expression levels could provide additional prognostic information. METHODS AND MATERIALS: More than 1,800 RCCs were analyzed in a tissue microarray (TMA) format for CAIX expression. All tumors had been reviewed and newly classified according to the WHO 2016 classification...
October 12, 2018: Urologic Oncology
Matthew D Ingham, Richard J Lee, Dhara MacDermed, Aria F Olumi
INTRODUCTION: As the transgender patient population continues to increase, urologists and other providers who treat genitourinary malignancies will increasingly encounter cases of prostate cancer in transgender women. Little exists in the current literature to help summarize the challenges and opportunities which face this unique patient population. Similarly, little exists to provide guidance on how we may best diagnose, manage, and follow transgender women diagnosed with prostate cancer...
October 12, 2018: Urologic Oncology
Savvas Omorphos, Zia Saad, Alex Kirkham, Raj Nigam, Peter Malone, Jamshed Bomanji, Asif Muneer
PURPOSE: To define the anatomical location of sentinel lymph nodes (SLN) in penile cancer patients based on Daseler's original zonal description using a combination of single photon emission computed tomography-computed tomography (SPECT-CT), cross sectional imaging and lymphoscintigraphy and characterise the limits of Zone V. MATERIALS AND METHODS: Patients with primary penile cancer ≥T1G2 were included in the study. A total of 113 groins with impalpable inguinal lymph nodes (cN0) underwent planar lymphoscintigraphy and SPECT-CT...
October 12, 2018: Urologic Oncology
Guangxi Sun, Xingming Zhang, Junru Chen, Banghua Liao, Zhenhua Liu, Jinge Zhao, Allen C Gao, Yaojing Yang, Kunpeng Shu, Jiandong Liu, Peng Zhao, Pengfei Shen, Hao Zeng
We conducted a systematic network meta-analysis to review the relevant literature evaluating the therapeutic efficacy of upfront docetaxel (Doc) or abiraterone (Abi) plus androgen deprivation therapy (ADT) on oncological outcome in patients with castration-naïve prostate cancer (CNPC). An attempt to identify subgroups of patients who would benefit most either from Doc or Abi plus ADT and further compare the efficacy and safety between these two combination therapies was made. A comprehensive search of the PubMed/Medline, Embase databases, International Clinical Trial Registration Platform (ICTRP), Clinical Trial, and Cochrane Central Register of Controlled Trials to December 2017 was performed...
October 10, 2018: Urologic Oncology
Mounsif Azizi, Juan Chipollini, Charles C Peyton, Salim K Cheriyan, Philippe E Spiess
Penile squamous cell carcinoma is a rare cancer in men. The main prognosticators of survival for penile cancer patients remain the presence and the extent of lymph node metastasis. While radical inguinal lymphadenectomy has been the cornerstone of regional lymph node management for many years, it is still associated with significant morbidity and psychological distress. Recent developments in penile squamous cell carcinoma management have been met with some controversy in the urologic oncology community. Herein, we review the current controversies and developments on the role of inguinal lymphadenectomy for penile cancer...
October 6, 2018: Urologic Oncology
Davide Bimbatti, Chiara Ciccarese, Emanuela Fantinel, Teodoro Sava, Francesco Massari, Iolanda Bisogno, Mario Romano, Antonio Porcaro, Matteo Brunelli, Guido Martignoni, Renzo Mazzarotto, Walter Artibani, Giampaolo Tortora, Roberto Iacovelli
BACKGROUND: Despite important results achieved for metastatic renal cell carcinoma, some patients could benefit from local treatments or an initial active surveillance (AS) period for recurrent disease. We aim to analyze: changes in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk class, the number of metastases and the disease burden from the start of AS to the beginning of systemic therapy; and if these changes influenced patient outcomes. PATIENTS AND METHODS: Patients who started AS at our institution from January 2007 to April 2016 were included...
October 6, 2018: Urologic Oncology
Giancarlo Marra, Guillaume Ploussard, Piet Ost, Pieter J L De Visschere, Alberto Briganti, Giorgio Gandaglia, Derya Tilki, Christian I Surcel, Igor Tsaur, Roderick C N Van Den Bergh, Alexander Kretschmer, Hendrik Borgmann, Paolo Gontero, Hashim U Ahmed, Massimo Valerio
INTRODUCTION: The urological community's opinion over focal therapy (FT) for prostate cancer (PCa) has never been assessed. Our aim was to investigate the current opinion on FT in the European urological community. METHODS: A 25-item questionnaire was devised according to the Cherries checklist and distributed through SurveyMonkey using a web link from November 2016 to October 2017. After a pilot validation (n = 40 urologists), the survey was sent through EAU and 9 other national European urological societies mailing list...
October 6, 2018: Urologic Oncology
Liu-Jia-Zi Shao, Fu-Shan Xue, Rui-Juan Guo, Li Zheng
No abstract text is available yet for this article.
September 30, 2018: Urologic Oncology
Alejandro Suárez-Bonnet, Claire Willis, Rachel Pittaway, Ken Smith, Tim Mair, Simon L Priestnall
OBJECTIVES: To evaluate the expression of COX-2, E-cadherin, vimentin, 14-3-3σ, and Phosphatase and tensin homolog (PTEN) tumor-related proteins in equine penile papillomas (ePP) and squamous cell carcinomas (ePSCC), the occurrence of epithelial-mesenchymal transition (EMT) at the invasion front (IF) and compare our findings with current knowledge on human penile squamous cell carcinoma (hPSCC). MATERIAL AND METHODS: We analyzed, by immunohistochemistry in 45 equine penile proliferative epithelial lesions, the expression of COX-2, E-cadherin, vimentin, 14-3-3σ, and PTEN using monoclonal antibodies...
September 27, 2018: Urologic Oncology
Andrea Minervini, Riccardo Campi, Fabrizio Di Maida, Andrea Mari, Ilaria Montagnani, Riccardo Tellini, Agostino Tuccio, Giampaolo Siena, Gianni Vittori, Alberto Lapini, Maria Rosaria Raspollini, Marco Carini
OBJECTIVE: Tumor enucleation has been shown to be oncologically safe for elective treatment of renal cell carcinoma (RCC); yet, evidence on long-term oncologic outcomes after robotic tumor enucleation is lacking. In this study we provide a detailed histopathological analysis of tumor-parenchyma interface and the long-term oncologic outcomes after robotic tumor enucleation for sporadic RCC in a high-volume referral center. MATERIALS AND METHODS: We selected consecutive patients undergoing robotic tumor enucleation for sporadic RCC by experienced surgeons with at least 4 years of follow-up...
September 27, 2018: Urologic Oncology
Jörg Hänze, Peter Rexin, Peter Jakubowski, Henner Schreiber, Hendrik Heers, Susanne Lingelbach, Ralf Kinscherf, Eberhard Weihe, Rainer Hofmann, Axel Hegele
Innervation of prostate cancer (CaP) tissue favors tumor progression and metastasis but the regulation of innervation in CaP is unclear. The oncogenic transcription factor ERG is commonly induced by a typical TMPRSS2-ERG (TE) gene fusion in CaP and may affect innervation. Here, we analyzed whether nerve density of CaP tissue is related to TE status or perineural infiltration status of CaP tissue. In parallel, we measured several members of the neuropilin/plexin/semaphorin family (NRP, PLXN, and SEMA) as possible targets mediating innervation...
September 18, 2018: Urologic Oncology
Weranja Ranasinghe, Daswin de Silva, Tharindu Bandaragoda, Achini Adikari, Damminda Alahakoon, Raj Persad, Nathan Lawrentschuk, Damien Bolton
BACKGROUND: The advantages of Robot-assisted laparoscopic prostatectomy (RARP) over open radical prostatectomy (ORP) in Prostate cancer perioperatively are well-established, but quality of life is more contentious. Increasingly, patients are utilising online cancer support groups (OCSG) to express themselves. Currently there is no method of analysis of these sophisticated data sources. We have used the PRIME-2 (Patient Reported Information Multidimensional Exploration version 2) framework for automated identification and intelligent analysis of decision-making, functional and emotional outcomes in men undergoing ORP vs...
September 17, 2018: Urologic Oncology
Reece Miller, Jonathan E Heinlen
BACKGROUND: Clostridium difficile infection (CDI) is an important cause of hospital acquired morbidity with implications for quality of care. Radical cystectomy is a surgical procedure associated with high rates of morbidity one of which is a high rate of CDI. The rate of CDI among patients undergoing radical cystectomy may be estimated based on the reports from single institutions or by querying national databases. This study aims to compare rates of CDI reported in single institution series with rates obtained from national datasets...
September 15, 2018: Urologic Oncology
Amirali Salmasi, Izak Faiena, Andrew T Lenis, Aydin Pooli, David C Johnson, Alexandra Drakaki, Kiran Gollapudi, Jeremy Blumberg, Allan J Pantuck, Karim Chamie
BACKGROUND: Although tumor tract seeding from renal mass biopsy (RMB) is exceedingly rare, the possibility of tumor capsule violation from RMB leading to perinephric fat invasion has not been quantified. We evaluated the association between RMB and perinephric fat invasion in patients with clinical T1a renal cell carcinoma who underwent partial or radical nephrectomy. MATERIALS AND METHODS: We reviewed the National Cancer Database from 2010-2013 and identified patients who underwent surgery for clinical T1a tumors...
September 15, 2018: Urologic Oncology
Matthew J Ferris, Yuan Liu, Jingning Ao, Jim Zhong, Mustafa Abugideiri, Theresa W Gillespie, Bradley C Carthon, Mehmet A Bilen, Omer Kucuk, Ashesh B Jani
In attempt to improve long-term disease control outcomes for high-risk prostate cancer, numerous clinical trials have tested the addition of chemotherapy (CTX)-either adjuvant or neoadjuvant-to definitive local therapy, either radical prostatectomy (RP) or radiation therapy (RT). Neoadjuvant trials generally confirm safety, feasibility, and pre-RP PSA reduction, but rates of pathologic complete response are rare, and no indications for neoadjuvant CTX have been firmly established. Adjuvant regimens have included CTX alone or in combination with androgen deprivation therapy (ADT)...
November 2018: Urologic Oncology
Igor Tsaur, Isabel Heidegger, Alexander Kretschmer, Hendrik Borgmann, Cristian Mirvald, Giorgio Gandaglia, Alberto Briganti, Roderick van den Bergh, Derya Tilki, Piet Ost, Guillaume Ploussard, Cristian Surcel
Recently, a plethora of life-prolonging cytotoxic, next-generation hormonal, immunotherapeutical as well as radionuclide therapies has emerged as a standard care for metastasized castration-resistant prostate cancer. Being strikingly effective in cancer control, these novel therapies might in fact exert a beneficial impact on skeletal events. Therefore, combining anticancer drugs with osteoprotective agents might lead to additional clinical advantage but must be weighed against simultaneously exposing patients to serious toxicities...
November 2018: Urologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"